Iannantuoni, F.; M. de Marañon, A.; Diaz-Morales, N.; Falcon, R.; Bañuls, C.; Abad-Jimenez, Z.; Victor, V.M.; Hernandez-Mijares, A.; Rovira-Llopis, S.
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. J. Clin. Med. 2019, 8, 1814.
https://doi.org/10.3390/jcm8111814
AMA Style
Iannantuoni F, M. de Marañon A, Diaz-Morales N, Falcon R, Bañuls C, Abad-Jimenez Z, Victor VM, Hernandez-Mijares A, Rovira-Llopis S.
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. Journal of Clinical Medicine. 2019; 8(11):1814.
https://doi.org/10.3390/jcm8111814
Chicago/Turabian Style
Iannantuoni, Francesca, Aranzazu M. de Marañon, Noelia Diaz-Morales, Rosa Falcon, Celia Bañuls, Zaida Abad-Jimenez, Victor M. Victor, Antonio Hernandez-Mijares, and Susana Rovira-Llopis.
2019. "The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes" Journal of Clinical Medicine 8, no. 11: 1814.
https://doi.org/10.3390/jcm8111814
APA Style
Iannantuoni, F., M. de Marañon, A., Diaz-Morales, N., Falcon, R., Bañuls, C., Abad-Jimenez, Z., Victor, V. M., Hernandez-Mijares, A., & Rovira-Llopis, S.
(2019). The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. Journal of Clinical Medicine, 8(11), 1814.
https://doi.org/10.3390/jcm8111814
